Skip to main content
. Author manuscript; available in PMC: 2008 Dec 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2007 Dec;13(12):1499–1507. doi: 10.1016/j.bbmt.2007.09.004

Figure 2. Cumulative incidence of recurrent malignancy and non-relapse mortality (NRM) according to HCT-comorbidity index (CI) and relapse risk categories.

Figure 2

The combined groups of patients with related and unrelated donors were categorized according to the presence of pretransplant comorbidities (HCT-CI: 0, 1-2, and ≥ 3) [18] (A, B) and the predicted risk of recurrent malignancy (low, intermediate, and high) [35] (C, D). The cumulative incidence rates of recurrent malignancy (A, C) and NRM (B, D) are shown for respective subgroups of patients.